Activity and Safety of Oral Administration of SSR150106XB for the Reduction of Inflammation in Patients With Active Rheumatoid Arthritis

• Status: Completed
• Trial end date: 2008-06-01

Summary

The primary objective of this study is to assess the reduction of systemic inflammation as measured by serum levels of C-reactive protein (CRP).

The secondary objectives are:

• to assess the reduction of systemic inflammation as measured changes in acute phase protein, serum amyloid A (SAA) and cytokine interleukin-6 (IL-6), and clinical American College of Rheumatology response rate, and morning stiffness duration;

• to assess the effect on pain relief within first 14 days;

• to obtain evidence of the safety and tolerability of SSR150106;

• to document trough plasma levels of SSR150106 and its first metabolite.

• Phase: Phase 2

Details

• Lead Sponsor: Sanofi